The signaling molecules that drive cancer. Understand how aberrant protein activity leads to disease—and why measuring activation state reveals what expression cannot.
Cancer is fundamentally a disease of dysregulated signaling. Oncoproteins—whether mutated, overexpressed, or constitutively active—drive uncontrolled proliferation, survival, and invasion. Targeting these proteins has transformed cancer treatment: imatinib for BCR-ABL, trastuzumab for HER2, erlotinib for EGFR. For many patients, these therapies have meant the difference between months and years of life.
But here's the difficult reality: the presence of a target doesn't guarantee response. HER2+ patients sometimes fail trastuzumab. EGFR+ patients sometimes fail erlotinib. For patients who have pinned their hopes on a targeted therapy, this uncertainty is agonizing. Why do some respond while others don't? Because expression tells you the protein is there; it doesn't tell you the protein is active or engaged with its partners.
FLIM-FRET offers a path toward better answers. By measuring activation states and dimerization directly, we can work toward distinguishing patients with active, druggable targets from those whose targets are present but functionally silent—reducing uncertainty in treatment selection.
The PI3K/Akt pathway sits at the center of cell survival signaling. When Akt (also known as PKB) is activated—phosphorylated at specific residues—it promotes survival, growth, and metabolism. This activation state, not expression level, predicts clinical outcomes. In renal cell carcinoma, FLIM-measured Akt activation stratified patients where expression-based measures showed no correlation with survival.
EGFR was among the first oncoproteins successfully targeted with small molecules. But the journey revealed complexity: EGFR mutations, not just expression, predict response to tyrosine kinase inhibitors. Even among mutant-positive patients, outcomes vary. The receptor's functional state—whether it's actively signaling—matters as much as whether it's present or mutated.
HER2 is the poster child for expression-based biomarkers: IHC scoring, FISH amplification testing, established clinical cutoffs. But here's what expression misses: HER2's most potent signaling occurs when it dimerizes with HER3. The HER2-HER3 heterodimer is the most mitogenic receptor combination known. Measuring this dimerization—not just HER2 expression—may identify patients who benefit from HER2-targeted therapy even below conventional thresholds.
KRAS was long considered undruggable—a smooth protein surface with no obvious binding pocket. Recent breakthroughs (sotorasib, adagrasib) have finally yielded targeted therapies for the G12C mutation. But KRAS biology is complex: it's a molecular switch that cycles between active and inactive states. Understanding when KRAS is "on" may help predict response to these new therapies.
BRAF V600E is one of the clearest examples of successful targeted therapy—vemurafenib and dabrafenib produce dramatic responses in mutant-positive melanoma. But even here, resistance emerges and outcomes vary. BRAF signals through the MAPK pathway, and understanding downstream pathway activity may help identify patients likely to develop resistance or benefit from combination strategies.
You now understand how oncoproteins drive cancer and why functional measurement matters. The next step is seeing how this translates to patient care—from sample preparation through clinical decision-making.
Continue to Sample & Methods
